Biopharmaceutical company Amgen (NASDAQ:AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after the closing bell. Wall Street expects the company to report a 7.9% ...

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results , with sales up 10.9% year on year to $9.09 billion. The ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Revenue rose to $9.1 billion, outpacing the estimated $8.88 billion, up 11% year over year. Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong ...

For the fourth quarter, Amgen’s revenues and earnings per share (EPS) are expected to decline slightly, primarily due to minor revenue adjustments. Looking ahead to 2025 and 2026, while there is ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

The drug entered Phase 1 trials late in 2024. As for the report itself, Amgen reported earnings per share (EPS) of $5.31 on revenue of $9.09 billion. Both numbers beat analysts’ estimates for an ...

Wall Street expects the company to report a 7.9% increase in earnings per share to $5.08, on a revenue of $8.87B, up 8.2% from last year. Analysts at BMO Capital Markets expect Amgen’s 2025 ...

Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.